BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Torres-Ortega PV, Saludas L, Hanafy AS, Garbayo E, Blanco-Prieto MJ. Micro- and nanotechnology approaches to improve Parkinson's disease therapy. J Control Release 2019;295:201-13. [PMID: 30579984 DOI: 10.1016/j.jconrel.2018.12.036] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Chidambaram SB, Ray B, Bhat A, Mahalakshmi AM, Sunanda T, Jagadeeswari P, Gowrav MP, Chandra R, Sakharkar MK. Mitochondria-targeted drug delivery in neurodegenerative diseases. Delivery of Drugs. Elsevier; 2020. pp. 97-117. [DOI: 10.1016/b978-0-12-817776-1.00005-5] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Bondarenko O, Saarma M. Neurotrophic Factors in Parkinson's Disease: Clinical Trials, Open Challenges and Nanoparticle-Mediated Delivery to the Brain. Front Cell Neurosci 2021;15:682597. [PMID: 34149364 DOI: 10.3389/fncel.2021.682597] [Reference Citation Analysis]
3 Stefani A, Pierantozzi M, Cardarelli S, Stefani L, Cerroni R, Conti M, Garasto E, Mercuri NB, Marini C, Sucapane P. Neurotrophins as Therapeutic Agents for Parkinson’s Disease; New Chances From Focused Ultrasound? Front Neurosci 2022;16:846681. [DOI: 10.3389/fnins.2022.846681] [Reference Citation Analysis]
4 Garbayo E, Pascual‐gil S, Rodríguez‐nogales C, Saludas L, Estella‐hermoso de Mendoza A, Blanco‐prieto MJ. Nanomedicine and drug delivery systems in cancer and regenerative medicine. WIREs Nanomed Nanobiotechnol 2020;12. [DOI: 10.1002/wnan.1637] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
5 Cunha A, Gaubert A, Latxague L, Dehay B. PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases. Pharmaceutics 2021;13:1042. [PMID: 34371733 DOI: 10.3390/pharmaceutics13071042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Rai M, Yadav A, Ingle AP, Reshetilov A, Blanco-prieto MJ, Feitosa CM. Neurodegenerative Diseases: The Real Problem and Nanobiotechnological Solutions. In: Rai M, Yadav A, editors. Nanobiotechnology in Neurodegenerative Diseases. Cham: Springer International Publishing; 2019. pp. 1-17. [DOI: 10.1007/978-3-030-30930-5_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Lewitt PA, Lipsman N, Kordower JH. Focused ultrasound opening of the blood–brain barrier for treatment of Parkinson's disease. Mov Disord 2019;34:1274-8. [DOI: 10.1002/mds.27722] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
8 Limongi T, Canta M, Racca L, Ancona A, Tritta S, Vighetto V, Cauda V. Improving dispersal of therapeutic nanoparticles in the human body. Nanomedicine (Lond) 2019;14:797-801. [PMID: 30895871 DOI: 10.2217/nnm-2019-0070] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
9 Bhattamisra SK, Shak AT, Xi LW, Safian NH, Choudhury H, Lim WM, Shahzad N, Alhakamy NA, Anwer MK, Radhakrishnan AK, Md S. Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson's disease. Int J Pharm 2020;579:119148. [PMID: 32084576 DOI: 10.1016/j.ijpharm.2020.119148] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 16.0] [Reference Citation Analysis]
10 Xiao M, Xiao ZJ, Yang B, Lan Z, Fang F. Blood-Brain Barrier: More Contributor to Disruption of Central Nervous System Homeostasis Than Victim in Neurological Disorders. Front Neurosci 2020;14:764. [PMID: 32903669 DOI: 10.3389/fnins.2020.00764] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
11 Mukherjee S, Madamsetty VS, Bhattacharya D, Roy Chowdhury S, Paul MK, Mukherjee A. Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics. Adv Funct Mater 2020;30:2003054. [DOI: 10.1002/adfm.202003054] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 9.5] [Reference Citation Analysis]
12 Luo S, Du L, Cui Y. Potential Therapeutic Applications and Developments of Exosomes in Parkinson’s Disease. Mol Pharmaceutics 2020;17:1447-57. [DOI: 10.1021/acs.molpharmaceut.0c00195] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
13 Torres-Ortega PV, Smerdou C, Ansorena E, Ballesteros-Briones MC, Martisova E, Garbayo E, Blanco-Prieto MJ. Optimization of a GDNF production method based on Semliki Forest virus vector. Eur J Pharm Sci 2021;159:105726. [PMID: 33482318 DOI: 10.1016/j.ejps.2021.105726] [Reference Citation Analysis]
14 Riccardi C, Napolitano F, Montesarchio D, Sampaolo S, Melone MAB. Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases. Pharmaceutics 2021;13:1897. [PMID: 34834311 DOI: 10.3390/pharmaceutics13111897] [Reference Citation Analysis]
15 Torfeh A, Abdolmaleki Z, Nazarian S, Shirazi Beheshtiha SH. Modafinil-coated nanoparticle increases expressions of brain-derived neurotrophic factor, glial cell line-derived neurotrophic factor and neuronal nuclear protein, and protects against middle cerebral artery occlusion-induced neuron apoptosis in the rat hippocampus. Anat Rec (Hoboken) 2021;304:2032-43. [PMID: 33345406 DOI: 10.1002/ar.24581] [Reference Citation Analysis]
16 Corrêa JAF, Evangelista AG, Nazareth TDM, Luciano FB. Fundamentals on the molecular mechanism of action of antimicrobial peptides. Materialia 2019;8:100494. [DOI: 10.1016/j.mtla.2019.100494] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
17 Nguyen TT, Dung Nguyen TT, Vo TK, Tran NM, Nguyen MK, Van Vo T, Van Vo G. Nanotechnology-based drug delivery for central nervous system disorders. Biomed Pharmacother 2021;143:112117. [PMID: 34479020 DOI: 10.1016/j.biopha.2021.112117] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Jarrin S, Hakami A, Newland B, Dowd E. Growth Factor Therapy for Parkinson's Disease: Alternative Delivery Systems. J Parkinsons Dis 2021. [PMID: 33896851 DOI: 10.3233/JPD-212662] [Reference Citation Analysis]
19 Bhatti GK, Gupta A, Pahwa P, Khullar N, Singh S, Navik U, Kumar S, Mastana SS, Reddy AP, Reddy PH, Bhatti JS. Targeting Mitochondrial bioenergetics as a promising therapeutic strategy in metabolic and neurodegenerative diseases. Biomed J 2022:S2319-4170(22)00074-9. [PMID: 35568318 DOI: 10.1016/j.bj.2022.05.002] [Reference Citation Analysis]
20 Liu H, Han Y, Wang T, Zhang H, Xu Q, Yuan J, Li Z. Targeting Microglia for Therapy of Parkinson's Disease by Using Biomimetic Ultrasmall Nanoparticles. J Am Chem Soc 2020;142:21730-42. [PMID: 33315369 DOI: 10.1021/jacs.0c09390] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
21 Ray B, Bhat A, Mahalakshmi AM, Tuladhar S, Bishir M, Mohan SK, Veeraraghavan VP, Chandra R, Essa MM, Chidambaram SB, Sakharkar MK. Mitochondrial and Organellar Crosstalk in Parkinson's Disease. ASN Neuro 2021;13:17590914211028364. [PMID: 34304614 DOI: 10.1177/17590914211028364] [Reference Citation Analysis]
22 Zhang X, Zhou J, Gu Z, Zhang H, Gong Q, Luo K. Advances in nanomedicines for diagnosis of central nervous system disorders. Biomaterials 2021;269:120492. [PMID: 33153757 DOI: 10.1016/j.biomaterials.2020.120492] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]